We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Arrowhead Pharmaceuticals Inc | NASDAQ:ARWR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.36 | 1.47% | 24.80 | 24.78 | 24.81 | 24.94 | 24.24 | 24.56 | 255,069 | 18:34:57 |
From May 2019 to May 2024
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead’s president and chief executive officer Christopher Anzalone, Ph.D., will present a corporate overview at the Jefferies 2015 Healthcare Conference on June 3, 2015 at 10:00 a.m. EDT.
Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page of the Company's website at http://ir.arrowheadresearch.com/events.cfm.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.
Source: Arrowhead Research Corporation
View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005435/en/
Arrowhead Research CorporationVince Anzalone, CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout GroupTodd James646-378-2926ir@arrowres.comorMedia:Russo PartnersMatt Middleman, M.D.212-845-4272matt.middleman@russopartnersllc.com
1 Year Arrowhead Pharmaceuticals Chart |
1 Month Arrowhead Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
